Literature DB >> 33127297

Safety of Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients With Multi-Vesel Disease: Sub-Analysis of the Japanese Retrograde Summit Registry.

Hiromasa Katoh1, Masahisa Yamane2, Toshiya Muramatsu3, Atsunori Okamura4, Yoshifumi Kashima5, Shunsuke Matsuno6, Masami Sakurada7, Mikihiro Kijima8, Masaki Tanabe9, Maoto Habara10.   

Abstract

BACKGROUND: The success rate of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) has gradually increased thanks to the continuous development of devices and techniques. However, the impact of multi-vessel disease (MVD) on its success rate and safety is not well known.
METHODS: The clinical records of 5009 patients enrolled in the Japanese Retrograde Summit Registry and who had undergone PCI for CTO at 65 centers between 2012 and 2015 were reviewed. We compared the outcome for patients with and without MVD.
RESULTS: Two thousand nine hundred and seventy-eight patients (59%) had MVD. Although there was no significant difference in the J-CTO score between the two groups [MVD group 1.51 ± 1.07 vs. SVD group 1.48 ± 1.07, p = 0.48], the procedural success rate of CTO-PCI in the MVD group was significantly lower than that in the SVD group (87.2% vs. 90.2%, p = 0.001). However, occurrence of procedure-related adverse events (4% vs. 5%, p = 0.11), total fluoroscopy (70 ± 45 min vs. 69 ± 50 min, p = 0.75) and procedural time (154 ± 86 min vs. 151 ± 89 min, p = 0.36), and total amount of contrast media (219 ± 102 mL vs. 222 ± 105 mL, p = 0.33) did not differ between the two groups.
CONCLUSIONS: Although MVD had an impact on the success rate of CTO-PCI, it did not affect procedure-related adverse events.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic coronary total occlusion; Multiple vessel disease; Percutaneous coronary intervention

Year:  2020        PMID: 33127297     DOI: 10.1016/j.carrev.2020.10.007

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  1 in total

Review 1.  CTO in Contemporary PCI.

Authors:  Mohamed Farag; Mohaned Egred
Journal:  Curr Cardiol Rev       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.